ResMed Inc. (RMD)
NYSE: RMD · Surgical & Medical Instruments & Apparatus · San Diego, CA · filing with the SEC since 1996
Grade6.8
◀ Past 6.9● Present 7.8▶ Future 5.4
Who owns ResMed Inc.
As filed with the SECHolders of 5% or more
3
Vanguard Capital Management holds 8.21% of Common Stock, as its SCHEDULE 13G filed Apr 29, 2026 says.
Directors and officers
16
report now, of 29 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Vanguard Capital Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
AustralianSuper Pty Ltd
SCHEDULE 13G · filed Aug 7, 2026 · Ordinary Shares
Vanguard Portfolio Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 13.7% in Oct 30, 2025
What RMD reports owning in othersstakes of 5% or more, and other ties
Nyxoah SA NYXH
SCHEDULE 13G/A · filed Jul 1, 2026 · Ordinary Shares, no nominal value per share · reported falling below 5%
Other ties the annual report names
Noctrix Health, LLC
A company bought · acquisition · May 2026 · owns, named in the 10-K filed Aug 13, 2026
29 subsidiaries in 9 countries, from the list filed with the 10-K filed Aug 13, 2026.
Insider tradesForm 4
29sales
0purchases
29sales on a scheduled plan
5people selling
$20.2Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 13, 2025 to Nov 13, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 13, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 29 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Farrell Michael J. | Chairman and CEO | 12 | $13.8M | 12 | 0 | $0 |
| Farrell Peter C | Chairman of the Board | 7 | $4.5M | 7 | 0 | $0 |
| Sandercock Brett | Chief Financial Officer | 5 | $1.2M | 5 | 0 | $0 |
| De Witte Jan | director | 1 | $500,000 | 1 | 0 | $0 |
| Rider Michael J | Global General Counsel | 4 | $100,000 | 4 | 0 | $0 |